Some studies suggest that, in CLL, 2p gains as a whole may associate with poor risk features, such as advanced stage, unmutated IGHV genes, and 17p13 deletion [4] [5] [6] . Our results are consistent with these observations and suggest that, among individual proto-oncogenes included in the 2p amplicon, poor prognosis may be heralded by gain of MYCN. The relevance of MYCN gain in determining CLL prognosis is also suggested by the observation that, in our cohort, the negative prognostic impact associated with gain of MYCN appears to be independent of stage at presentation, IGHV mutation status, or presence of 17p13 deletion. Future studies are required to validate these results in larger patient populations. 